All locations are open for appointments and procedures, including COVID-19 testing. Schedule an appointment online or call your doctor’s office. Patients may be accompanied by visitors. Read our updated visitor policy.

If you need help accessing our website, call 855-698-9991
Skip to main content
Sripal Bangalore at [NYU Langone Health]
NYU Langone Provider

Sripal Bangalore, MD

NYU Langone Provider
  • Specialties: Interventional Cardiology, Cardiology
  • Languages: English, Hindi
  • Phone: 212-263-5656
View Locations
Director of Research
Cardiac Catheterization Laboratory
Published
More Than 400 Peer-Reviewed Medical Journal Articles
More Than $12 Million in Research Grants, Including from the National Heart, Lung, and Blood Institute
National Expert
Coronary Angioplasty in Chronic Kidney Disease Patients

My goal as an interventional cardiologist is to improve the lives of people who have complex coronary artery disease. This includes people with severely blocked or narrowed arteries and chronic total occlusion, which occurs when an artery is completely blocked for three or more months.

I also specialize in using angioplasty to open blocked coronary arteries for people who have chronic kidney disease. Coronary angioplasty generally relies on the use of contrast dye to makes blockages visible. However, for people with chronic kidney disease the dye can further worsen kidney function and increase the chance of needing dialysis. To limit the impact on kidney function, I use as little dye as possible, and sometimes none at all.

When I meet with patients, I want to understand their individual needs. I discuss their symptoms and test results and ask how the heart condition is affecting their everyday lives, because treatment for blocked arteries is not a one-size-fits-all endeavor. I strive to determine the treatment that is most likely to improve a person’s quality of life in the least invasive way.

I use advanced stenting technology and best-in-class stents. My treatment recommendations are based on evidence from clinical studies and national and international society practice guidelines, many of which I participate in. Ultimately, my goal is to determine the treatment plan that is most likely to result in the best short- and long-term outcomes for my patients.

I am actively involved in research comparing the effectiveness of different cardiovascular disease treatments, including medication and stenting. I am the principal investigator of the ISCHEMIA-CKD trial, a randomized trial for patients with advanced chronic kidney disease and abnormal stress test, which is being carried out in 33 countries and up to 350 clinical sites. The trial tests the effectiveness of performing cardiac catheterization versus medical therapy alone for people who have chronic kidney disease. In addition, my research has compared the outcomes of stenting versus coronary bypass graft surgery for people with multiple blockages.

I have received several awards including the Dr. Gregory Braden Memorial Fellow of the Year Award from the Society for Cardiovascular Angiography and Interventions and the Douglas P. Zipes Distinguished Young Scientist Award from the American College of Cardiology. I have been awarded grants from the National Institutes of Health, Agency for Healthcare Research and Quality, and American Heart Association, as well as from the industry, and have published more than 400 articles in leading national and international journals.


Conditions and Treatments

Conditions
  • mitral valve stenosis
  • angina
  • aortic valve stenosis
  • heart muscle disease
  • claudication
  • coronary heart disease
  • peripheral vascular disease
  • arteriosclerosis
  • arterial occlusive disease
  • inflammation of the heart valve
  • critical limb ischemia
  • heart disease
  • renal artery stenosis
  • aortic valve disease
  • chest pain
  • carotid artery disease
  • high blood pressure disorder
  • heart attack
  • abnormal heart rhythms
  • aortic valve insufficiency
  • congestive heart failure
  • carotid stenosis
  • acute coronary syndrome
  • mitral valve regurgitation
Treatments
  • cardiac catheterization

Positions
Board Certifications
  • American Board of Internal Medicine (Interventional Cardiology), 2009
  • American Board of Internal Medicine (Cardiovascular Disease), 2008
Education and Training
  • Fellowship, Peter Bent Brigham Hospital, Interventional Cardiology, 2010
  • Fellowship, Mount Sinai (St. Luke's-Roosevelt Hospital Center), Cardiovascular Med, 2008
  • MD from Bangalore University, 2000

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

  • Aetna
    • Aetna HMO
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Agewell
    • Agewell
  • Amidacare
    • Amidacare
  • Centerlight
    • Centerlight
  • Cigna
    • Cigna EPO/POS
    • Cigna PPO
  • ElderPlan
    • ElderPlan
  • Emblem
    • Emblem Select Care Exchange
  • Empire Blue Cross Blue Shield
    • Empire Blue Cross Blue Shield EPO
    • Empire Blue Cross Blue Shield HMO
    • Empire Blue Cross Blue Shield HealthPlus
    • Empire Blue Cross Blue Shield HealthPlus Essential
    • Empire Blue Cross Blue Shield Indemnity
    • Empire Blue Cross Blue Shield MediBlue
    • Empire Blue Cross Blue Shield POS
    • Empire Blue Cross Blue Shield PPO
  • Fidelis
    • Fidelis Child Health
    • Fidelis Essential
    • Fidelis Exchange
    • Fidelis Medicaid
    • Fidelis Medicare
  • GHI
    • GHI CBP
    • GHI HMO
View All Accepted Plans This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Locations and Appointments

NYU Cardiac Catheterization Associates

550 1st Avenue, 14th Floor
New York, NY 10016

Research Summary

Dr. Bangalore is the PI of a multicenter, international, randomized controlled trial conducted to define the role of an invasive approach in patients with stable ischemic heart disease and substantial ischemia and chronic kidney disease (eGFR <30 or on dialysis). Patients with advanced CKD and moderate to severe ischemia on stress testing will be randomized to INV strategy of cath with optimal revascularization along with optimal medical therapy or to a CON strategy of optimal medical therapy alone with cath reserved for OMT failure. View the clinical trial.

In addition, his research interests are in comparative effectiveness studies for cardiovascular diseases, particularly stable ischemic heart disease, acute coronary syndromes, hypertension and dyslipidemia. Dr. Bangalore has received grants from the National Institutes of Health, Agency for Healthcare Research and Quality, American Heart Association and from the industry. 

 

These focus areas and their associated publications are derived from PubMed and the MeSH term library. *
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

  • BARCONA Trial: A Randomized Trial of Bardoxolone Methyl in Patients Infected with SARS-Corona Virus-2 (COVID-19)

    Learn More
  • CHEETAH:A Prospective Multicenter Study to Evaluate the Safety and Performance of the CAT RX Aspiration Catheter in Patients with a High Thrombus Burden Acute Coronary Vessel Occlusion

    Learn More
  • Heart Attack Research Program (HARP)

    Learn More
View All Research Studies (3)

Read All Publications (576)

Related News